| + |
BRD3 | up-regulates activity 
binding
|
EP300 |
0.323 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-262044 |
|
|
Homo sapiens |
RAW-264.7 Cell |
| pmid |
sentence |
| 28045112 |
Brd3 interacts with both IRF3 and p300, increases p300-mediated acetylation of IRF3, and enhances the association of IRF3 with p300 upon virus infection.|Brd3 enhances p300-mediated acetylation of IRF3 |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
CID 132010322 | down-regulates activity 
chemical inhibition
|
BRD3 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-261104 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 31969702 |
ABBV-744 potently inhibited the BD2 domain of BET family proteins with more than 290× selectivity relative to the BD1 domains of BRD2, BRD3 and BRD4 |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide | down-regulates activity
chemical inhibition
|
BRD3 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-262203 |
|
|
in vitro |
|
| pmid |
sentence |
| 24015967 |
This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4). This work has yielded a potent, selective compound I-BET762 that is now under evaluation |
|
| Publications: |
1 |
Organism: |
In Vitro |
| + |
2-[(9S)-7-(4-Chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[8-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]octyl]acetamide | down-regulates quantity
chemical inhibition
|
BRD3 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-261096 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 29764999 |
DBET6 induces efficient degradation of BET proteins and inhibits the proliferation of GBM cells |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
JQ1 | down-regulates activity
chemical inhibition
|
BRD3 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-261988 |
|
|
in vitro |
|
| pmid |
sentence |
| 20871596 |
Enantiomerically pure (+)-JQ1 bound with a Kd of about 50 nM and 90 nM to the first and second bromodomains of BRD4, respectively (Fig. 1c, Supplementary Table 3). Comparable binding to both domains of BRD3 was observed, whereas the first bromodomains of BRDT and BRD2 revealed about 3-fold weaker binding.|Here, we present a first, thoroughly characterized inhibitor of the BET-family of bromodomains. |
|
| Publications: |
1 |
Organism: |
In Vitro |
| + |
BRD7 | up-regulates quantity by expression 
transcriptional regulation
|
BRD3 |
0.392 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-253764 |
|
|
Homo sapiens |
Nasopharyngeal Carcinoma Cell |
| pmid |
sentence |
| 12600283 |
BRD7 protein could respectively interact with proteins, BRD2 and BRD3, and BRD7 could up-regulate the expression levels of BRD2 and BRD3 genes in mRNA level to some extent. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
3.0
BRD3
- 
- 